Tag
This multicentre study reveals that combining resting left atrial compliance with exercise stress echocardiography significantly improves diagnostic accuracy for HFpEF, potentially reducing the need for invasive testing in patients with une
Elevated endogenous insulin and insulin resistance independently predict progression of diastolic dysfunction and increased cardiovascular mortality, highlighting early metabolic dysregulation as a target to prevent heart failure with prese
This review comprehensively summarizes recent studies (2021–2024) from the EMPEROR-Preserved trial, highlighting empagliflozin’s consistent benefits on cardiovascular and renal outcomes, quality of life, and key clinical subgroups in HFpEF
The SUMMIT trial reveals that tirzepatide improves heart failure outcomes and quality of life in obese HFpEF patients with or without type 2 diabetes, despite attenuated weight loss in diabetic patients.
This analysis of the TOPCAT trial cohort evaluates the association between β-blocker use and health status in HFpEF patients, revealing no significant impact on baseline quality of life or modification of spironolactone benefits.
This phase 2 trial shows that volenrelaxin, a long-acting relaxin analog, failed to improve overall congestion or kidney function in HFpEF patients and was linked to worsening congestion and safety signals, despite modest left atrial functi
Real-world analysis shows semaglutide and tirzepatide reduce hospitalization for heart failure or all-cause mortality by over 40% in patients with cardiometabolic HFpEF, with no significant difference between the two drug options.
